Prime Medicine, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-201.1M | $-195.9M | $-198.1M | $-121.8M | $-165.4M | $-3.4M |
| Depreciation & Amortization | $7.3M | $6.1M | $4.7M | $2.2M | $568.0K | $43.0K |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $29.3M | $26.1M | $13.9M | $6.5M | $1.7M | $391.0K |
| Net Cash from Operating Activities | $-162.6M | $-122.9M | $-165.4M | $-131.8M | $-34.1M | $-5.5M |
| Investing Activities | ||||||
| Capital Expenditures | $4.5M | $7.3M | $8.7M | $16.1M | $4.2M | $639.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-108.8M | $68.5M | $18.7M | $-47.1M | $-73.6M | $-1.1M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $151.5M | $195.9M | $655.0K | $181.5M | $269.3M | $34.9M |
| Net Change in Cash | $-119.8M | $141.5M | $-146.0M | $2.6M | $161.6M | $28.3M |
| Free Cash Flow | $-167.1M | $-130.2M | $-174.1M | $-147.9M | $-38.2M | $-6.2M |
When you combine ignorance and leverage, you get some pretty interesting results.